Our Pricing

Are Wegovy and Ozempic the Same Medication in the UK?

Many patients ask whether Wegovy and Ozempic are the same medication, and the answer is both yes and no. Both contain the identical active ingredient—semaglutide, a GLP-1 receptor agonist—but they differ significantly in licensed indication, dosing schedule, and regulatory approval in the UK. Understanding these distinctions is essential for choosing the right treatment under clinical supervision.

Are Wegovy and Ozempic the Same Active Ingredient?

Yes, when asking are Wegovy and Ozempic the same in terms of active pharmaceutical ingredient, the answer is definitive: both contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk [1]. Semaglutide mimics the action of the naturally occurring GLP-1 hormone, which regulates blood sugar levels and appetite by slowing gastric emptying and enhancing insulin secretion.

The molecular structure of semaglutide in Wegovy is chemically identical to that in Ozempic. Both are administered via subcutaneous injection using a pre-filled pen device. However, despite sharing the same active ingredient, the two products are licensed for entirely different therapeutic purposes by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, which is a critical distinction for prescribers and patients alike [2].

How Are Wegovy and Ozempic the Same or Different in Licensing?

While are Wegovy and Ozempic the same medication chemically, their MHRA-approved indications differ substantially. Ozempic is licensed exclusively for the treatment of type 2 diabetes mellitus in adults, used alongside diet and exercise to improve glycaemic control. It is not approved for weight loss as a primary indication in the UK, although weight reduction is a recognised secondary effect observed in clinical trials [3].

Wegovy, by contrast, received UK marketing authorisation specifically for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension or dyslipidaemia [4]. This licensing distinction means that prescribing Ozempic for weight loss alone would constitute off-label use, which UK prescribers typically avoid unless clinically justified and documented.

Regulatory Approval Timeline in the UK

Ozempic was approved by the MHRA for type 2 diabetes in 2018, whereas Wegovy received UK approval for weight management in 2022. This regulatory timeline reflects the different clinical trial programmes underpinning each product. The STEP (Semaglutide Treatment Effect in People with Obesity) trials demonstrated Wegovy's efficacy for weight loss, with participants achieving an average reduction of 15% body weight over 68 weeks [4]. The SUSTAIN trials, meanwhile, established Ozempic's glucose-lowering efficacy in diabetic populations [3].

Are Wegovy and Ozempic the Same Dose and Strength?

No—this is where are Wegovy and Ozempic the same question becomes more nuanced. Although both medications use semaglutide, the maximum licensed doses differ significantly. Ozempic is available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg strengths, with the 2 mg dose representing the highest approved strength for diabetes management [3].

Wegovy, however, is titrated up to a maximum maintenance dose of 2.4 mg once weekly, which is 20% higher than the top Ozempic dose. This higher dose was specifically studied and approved for weight management, reflecting the dose-response relationship observed in the STEP trials [4]. The Wegovy titration schedule begins at 0.25 mg weekly and escalates gradually over 16–20 weeks to minimise gastrointestinal side effects, a protocol that differs from the Ozempic escalation guidance for diabetes.

Dose Escalation Protocols

For Wegovy, the recommended titration is: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1 mg (weeks 9–12), 1.7 mg (weeks 13–16), and 2.4 mg from week 17 onwards. For Ozempic, the typical initiation is 0.25 mg for four weeks, then 0.5 mg, with optional escalation to 1 mg or 2 mg based on glycaemic response. These differing protocols reflect the distinct therapeutic goals and patient populations for which each product is licensed.

Are Wegovy and Ozempic the Same Price in the UK?

Cost is another area where are Wegovy and Ozempic the same yields a clear answer: no. Wegovy is available at Cured Pharmacy from £69.00 per month, subject to clinical assessment and prescriber approval. This transparent upfront pricing includes the medication and clinical consultation with a UK-registered prescriber, with next-day delivery available across the UK.

Ozempic pricing varies depending on the strength and supplier, but it is generally positioned as a diabetes medication rather than a weight-loss treatment in the UK market. Patients seeking semaglutide specifically for weight management should be prescribed Wegovy rather than Ozempic, both for regulatory compliance and to ensure the appropriate dosing schedule is followed. Cured Pharmacy's superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all semaglutide prescriptions align with MHRA licensing and NICE guidance.

First-time patients at Cured Pharmacy can Save £20 off their first order using the code Weightlossnew, making Wegovy one of the most competitively priced weight-loss treatments available through a UK-registered online pharmacy (GPhC 9012511).

Are Wegovy and Ozempic the Same in Terms of Side Effects?

Because are Wegovy and Ozempic the same active ingredient—semaglutide—they share a very similar side effect profile. The most commonly reported adverse events in clinical trials for both medications include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during the dose escalation phase [1][4]. These gastrointestinal symptoms typically diminish over time as the body adapts to the medication.

Rare but serious side effects associated with semaglutide include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not conclusively in humans). Both Wegovy and Ozempic carry the same contraindications: they should not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2][3]. All patients must undergo a clinical assessment by a UK prescriber before starting either medication to evaluate individual risk factors.

Managing Gastrointestinal Symptoms

To minimise nausea and other GI side effects, patients are advised to follow the gradual dose escalation protocol, eat smaller meals, avoid high-fat foods, and stay well-hydrated. If symptoms persist or worsen, patients should consult their prescriber, who may adjust the titration schedule or recommend supportive measures. Both Wegovy and Ozempic require the same patient counselling regarding injection technique, storage, and disposal of pen devices.

Are Wegovy and Ozempic the Same When It Comes to Choosing Between Them?

The question are Wegovy and Ozempic the same ultimately depends on your therapeutic goal. If you have type 2 diabetes and require glycaemic control, Ozempic is the appropriate choice, as it is licensed and studied for that indication. If your primary goal is chronic weight management and you meet the BMI criteria (with or without comorbidities), Wegovy is the correct prescription, offering the higher 2.4 mg maintenance dose proven effective in the STEP trials [4].

In the UK, prescribing semaglutide off-label (e.g., using Ozempic for weight loss) is generally discouraged by NICE and the MHRA, as it circumvents the regulatory framework designed to ensure patient safety and appropriate use. Cured Pharmacy's clinical team follows strict protocols to ensure all semaglutide prescriptions align with current UK guidelines and that patients receive the medication licensed for their specific condition.

Both medications require ongoing clinical monitoring, lifestyle modification (diet and exercise), and adherence to the prescribed regimen. Neither Wegovy nor Ozempic is a standalone solution; they are adjuncts to a comprehensive weight management or diabetes care programme. Patients should have realistic expectations, understanding that average weight loss with Wegovy is around 15% of body weight over 68 weeks, while individual results vary [4].

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. [accessed 15 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2022). Public Assessment Report: Wegovy 2.4 mg solution for injection in pre-filled pen. MHRA. [accessed 15 August 2026]
3. Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. [accessed 15 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.